⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10902595 | 1.00 | — | — | |
| SCHEMBL18102293 | 0.76 | — | — | |
| SCHEMBL16046967 | 0.75 | GPR55 (0.39) | — | |
| SCHEMBL16046968 | 0.75 | GPR55 (0.39) | — | |
| SCHEMBL21549647 | 0.75 | — | — | |
| SCHEMBL19295802 | 0.75 | MAPK1 (0.34) | — | |
| SCHEMBL12268278 | 0.75 | — | — | |
| SCHEMBL22688559 | 0.75 | GPR55 (0.39) | — | |
| SCHEMBL14601171 | 0.75 | GPR55 (0.39) | — | |
| SCHEMBL9803634 | 0.73 | GAA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | claimed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | claimed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | claimed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | disclosed |
| EP-2827883-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-20170174727-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-06-22 | — | — | US | disclosed |
| US-8962563-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2827883-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxter International Inc (US) | 2015-01-28 | — | — | EP | disclosed |
| US-20130252896-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER HEALTHCARE SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
| US-5840758-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ABBOTT LABORATORIES (US) | 1998-11-24 | — | — | US | disclosed |
| US-4584014-A | PREEMERGENCE HERBICIDES;CORN, WHEAT AND OATS | ROHM AND HAAS COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| US-4584014-A | PREEMERGENCE HERBICIDES;CORN, WHEAT AND OATS | ROHM AND HAAS COMPANY (US) | 1986-04-22 | — | — | US | disclosed |